<DOC>
	<DOCNO>NCT01817738</DOCNO>
	<brief_summary>The purpose study determine whether new RNActive®-derived prostate cancer vaccine CV9104 prolongs survival patient asymptomatic minimally symptomatic metastatic prostate cancer castrate resistant .</brief_summary>
	<brief_title>Trial RNActive®-Derived Prostate Cancer Vaccine Metastatic Castrate-refractory Prostate Cancer</brief_title>
	<detailed_description>The study first clinical study new prostate cancer vaccine CV9104 . This vaccine compose 6RNActive®-based compound , encode antigen overexpressed prostate cancer compare healthy tissue . RNActive®-based vaccine novel class vaccine base messenger RNA . The study double-blind randomize placebo-controlled phase I/II trial men asymptomatic- minimally symptomatic metastatic castrate-refractory prostate cancer . The phase 1 ( safety lead- ) part trial primary objective ass safety CV9104 determine dose randomize phase II part . The primary objective phase II part compare overall survival patient treat CV9104 compare patient treat placebo .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Key 1 . Male , age ≥18 year 2 . Histologically confirm castrate refractory metastatic adenocarcinoma prostate progressive disease surgical castration androgen suppression therapy include GNRH agonist antagonist least 1 additional antihormonal manipulation ; serum testosterone level &lt; 50 ng/dL &lt; 1.7 nmol/L Progression confirm either radiologically 2 consecutive rise PSA , measure least 1 week apart , result least 50 % increase nadir PSA &gt; 2 ng/mL . An antiandrogen withdrawal response must exclude discontinuation antiandrogen therapy least 6 week . 3 . Metastatic disease confirm image 4 . ECOG performance status 0 1 Key 1 . Previous immunotherapy PCA ( e.g . sipuleucelT [ Provenge® ] , experimental cancer vaccine ipilimumab [ Yervoy® ] ) . 2 . Treatment investigational anticancer agent within 4 week prior first dose study drug 3 . Systemic treatment immunosuppressive agent 4 . Active skin disease ( atopic eczema , psoriasis ) area vaccine injection ( upper arm thigh ) prevent administration i.d . injection area healthy skin . 5 . History current autoimmune disorder 6 . Primary secondary immune deficiency . 7 . Seropositive human immunodeficiency virus , hepatitis B virus ( except hepatitis B vaccination ) hepatitis C virus infection . 8 . Symptomatic congestive heart failure ( New York Heart Association 3 4 ) , unstable angina pectoris myocardial infarction , significant cardiac arrhythmia , history stroke transient ischemic attack , within 6 month prior enrolment severe hypertension accord WHO criteria uncontrolled hypertension time enrolment ( systolic blood pressure ≥ 180 mm Hg ) ´ 9 . Previous chemotherapy metastatic PCA . 10 . Previous antihormonal treatment abiraterone investigational antihormonal treatment . 11 . Cancerrelated pain require opioid narcotic within 28 day enrolment average pain score &gt; 3 visual analogue scale . 12 . Presence visceral metastasis . 13 . History malignancy PCA last 5 year ( except basal cell carcinoma skin ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Castrate-refractory</keyword>
</DOC>